Using recombinant human GPVI, we evaluated the effect of N-linked glycosylation at the consensus site N 92 GS 94 on binding of this platelet-specific receptor to its ligands, human type I collagen, collagen-related peptide (CRP) and the snake venom C-type lectin convulxin (CVX). In COS-7 cells transiently transfected with GPVI, deglycosylation with PNGase F (specific for complex N-linked glycans) or tunicamycin decreases the molecular weight of GPVI and reduces transfected COS-7 cell binding to both CRP and CVX. In stably transfected Dami cells, the substitutions N92A or S94A, but not L95H, resulted in a 30-40% decrease in adhesion to CVX, but a 90% or greater decrease in adhesion to CRP and a 65-70% decrease in adhesion to type I collagen.
INTRODUCTION
Glycoprotein VI (GPVI) plays a key role in platelet adhesion to collagens and subsequent platelet activation 1,2 , is uniquely expressed by cells of the megakaryocytic lineage, and is a member of the immunoglobulin gene superfamily, closely related to FcαR and natural killer receptors 3, 4 . While GPVI binds specifically to polymerized collagens, it also has a high affinity for convulxin (CVX), a C-type lectin from the venom of the Tropical Rattlesnake, Crotalus durissus terrificus 5 and the synthetic, collagenrelated peptide (CRP) (Gly-Pro-Hyp) 10 6,7 .
Mouse and human GPVI cDNA exhibit a 67.3% similarity in nucleotide sequence 4 . One N-linked glycosylation site has been predicted in human GPVI and is located within extracellular domain D1 at residue N92. Mouse GPVI has a comparable consensus site at N93 plus an additional N-linked glycosylation site at N244 within D2 4 .
Lir-1 is another member of the Ig gene superfamily that is composed of two Iglike domains and has 44% sequence identity to GPVI. Figure 1 is an alpha-carbon trace of Lir-1 based on the crystal structure (PDB 1G0X) 8 and depicted as a continuous tube. In the upper left hand corner, the entire Lir-1 molecule is shown, with the extracellular domains D1 and D2 designated. In the enlarged image in the inset at the bottom right, selected residues within two predominant hydrophilic loops of D1 are highlighted in lighter color, and the GPVI residues that are positional homologs are indicated.
Certain of these residues are featured in the elegant model of the GPVI binding site for CVX proposed by Batuwangala et al. 9 . In that model, two charged sites on GPVI that span D1 and D2 were proposed to interact with two complementary charged
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From sites on CVX. One of the major sites (designated number 1 in that study) would span the sequence V54 to K61 in D1, and that sequence is a positional homolog to the Lir-1 hydrophilic loop depicted in this figure. The key GPVI residues implicit in this model are D55, R58, E60 and K61.
Additional binding site residues were identified by Lecut et al. 10 , who mapped the epitope on GPVI that is recognized by murine monoclonal antibody 9O12. Using phage display, they observed that V54 and L56 contribute to this epitope. Since 9O12 also inhibits the binding of collagen, CRP and CVX to GPVI, while other inhibitory antibodies, such as 3F8 or 9E18, had a differential effect on each ligand, they concluded that the CVX and CRP binding sites are distinct but overlapping. V54 and L56 happen to be located in the putative CVX binding loop proposed by Batuwangala et al. 9 .
The last two residues highlighted in Figure 1 (N92 and N94) would be situated on an adjacent hydrophilic loop. These contribute to a consensus N-linked glycosylation site N 92-G-S 94 and may influence ligand recognition. In this study, we analyzed the extent of N-linked glycosylation at this site and the effect of deglycosylation on the binding of GPVI to type I collagen, CRP, and CVX.
MATERIALS AND METHODS
Cells and Reagents. COS-7 and Dami cells were purchased from the ATCC (Rockville, MD). Convulxin (CVX) was purified from snake venom as previously described 11 . Synthetic peptides, including collagen-related peptide (CRP) [Gly-Cys-Pro-(Gly-Pro-Hyp) 10 -Gly-Cys-Pro-Gly], GPA [Gly-Cys-Pro-(Gly-Pro-Ala) 10 -Gly-Cys-Pro-Gly], Synthesis of human FcRγ chain cDNA. FcRγ chain cDNA was amplified from leukocyte RNA by RT-PCR using the forward primer 5'-GCCGATCTCCAAGCCAG-3' and the reverse primer 5'-TGAGGGCTGGAAGAACCAGA-3', based on the published sequence 12 . The amplified cDNA was subcloned in pGEM-T Easy, sequenced, and subcloned into pcDNA3.
Generation of N92A, S94A, and L95H by site-directed mutagenesis. Sitedirected mutagenesis was carried out using the Altered Sites II in vitro Mutagenesis System (Promega). Briefly, human GPVI cDNA was subcloned into the vector pAlter-1 (Promega) in a 3' to 5' orientation, and designated pAlter-hGP6. Mutagenic
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From oligonucleotides in reverse-complimentary sequence were synthesized as follows; N92A: 5'-GAGGCTTCCGGCCTGGTAGGAG-3'; S94A: 5'-GGACCAGAGGGCTCCGTTCTGG-3'; and L95H: 5'-CAGGGACCAGTGGCTTCCGTT-3'.
pAlter-hGP6 was purified using a Wizard Plus Midiprep kit (Promega). The mutant cDNAs were generated according to the manufacturer's instructions and subcloned into pcDNA3 (Invitrogen) for expression in COS-7 or Dami cells as surface membrane proteins 13, 14 .
Transient expression in COS-7 cells. COS-7 cells were first transfected with
FcRγ cDNA in pcDNA3, and stable COS-7 cell lines expressing FcRγ were selected by western blot of cell lysate proteins using rabbit anti-FcRγ antibody. A stable FcRγ expressing clone was then transfected with wild-type or mutant GPVI cDNA in pcDNA3.
Transfected cells were grown for 48 hours in the DNA containing media and then subjected to adhesion and ligand blotting assays. To normalize for transfection efficiency, luciferase activity was measured using the Luciferase Assay System (Promega).
Production of stable Dami transfectants. Wild-type GPVI, N92A, S94A and L95H, subcloned in pcDNA3, were separately transfected into Dami cells using the Effectene transfection system. Selection was carried out for 2 weeks in IMDM supplemented with 0.5 mg/ml Geneticin (GibcoBRL). The surviving cells were cloned to generate established stable cell lines that would be screened for adhesion to convulxin or CRP using a colorimetric assay 15 . were washed once in PBS and resuspended in 1 ml of TBS containing 2 mM EDTA.
Triton X-100 was added to a final concentration of 1 % (v/v), the mixture was gently Cell adhesion to CRP or CVX. Cell adhesion was quantitated by measuring the alkaline phosphatase activity of adherent cells using para-nitrophenylphosphate (PNPP), as described by Bellavite et al. 15 . Wells of a 96-well microtiter tray were coated with either 5 µg/ml CVX in phosphate-buffered saline, pH 7.4 or 10 µg/ml CRP in 10 mM acetic acid at 4˚C. The wells were blocked with 2% bovine serum albumin (BSA; Sigma) in TBS at ambient temperature for 60 minutes, then rinsed twice in TBS.
COS-7 cell transfectants were detached from culture flasks using 1 mM EDTA in PBS then washed once in TBS and resuspended at 10 6 cells/ml in TBS containing 0.5% For personal use only. on November 12, 2017. by guest www.bloodjournal.org From µl/well) was added, and the plates were gently and continuously agitated on a horizontal shaker for 60 minutes at ambient temperature. Color was developed by adding 2N NaOH (100 µl/well), and the absorbance at 405 nm of each well was recorded using an EIA reader.
Cell adhesion to type I collagen. Transfected Dami cell adhesion to type I collagen under static conditions was performed as described by Lecut et al. 17 and
Lagrue-Lak-Hal et al. 18 . Briefly, type I collagen (20 µg/ml) was immobilized in wells of
Immulon II microtiter plates by incubation for 1 hour at ambient temperature. The wells were blocked with BSA and washed as described above. A one hundred µl suspension of Dami cell transfectants (10 6 cells/ml) was added to each pre-coated well in triplicate and incubated at ambient temperature for 45 minutes with gentle agitation. Nonadherent cells were removed by gentle aspiration and rinsing with saline, then adherent cells were quantitated based on alkaline phosphatase activity, as described above.
Nonspecific adhesion was measured using wells coated only with BSA.
Measurement of surface expression of GPVI. Surface expression of GPVI was measured by flow cytometry using mouse anti-human GPVI monoclonal antibody 204-11 19 . After the cells were washed in PBS, as described above, 1 x 10 6 cells were resuspended in 19 µl of Tyrode's buffer (12mM NaHCO3, 2mM MgCl2, 137.5mM NaCl, 2.6mM KCl, pH 7.4) containing 1% (w/v) BSA, to which was added 1 µl of 204-11, previously diluted to 10 µg/ml in the same buffer. After a 30 minute incubation, 400 µl of PBS was added, and the amount of bound antibody was measured within 30 min using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). Data were analyzed with BD CellQuestPro software, and the amount of bound antibody was reported as the geometric mean fluorescence intensity (GMFI).
RESULTS
Transient expression of wild-type and N-deglycosylated human GPVI in COS-7 cells. COS-7 cells stably expressing human FcRγ chain were transiently transfected with wild-type GPVI or the mutants N92A or S94A. Transient expression of these constructs in complex with FcRγ permitted an initial assessment of the effect of these amino acid substitutions as well as enzymatic deglycosylation on the electrophoretic
properties, expression and function of GPVI. We must emphasize that the purpose of these experiments in transiently transfected COS-7 cells was to obtain initial qualitative comparisons of the GPVI mutants. These initial studies were then followed quantitative comparisons between mutants expressed in Dami cells, as described in the next section.
The ligand blot assay (Figure 2A ) using biotin-CVX permitted a simultaneous analysis of the electrophoretic properties of each construct and its ability to bind to CVX.
In SDS lysates from transfected COS-7 cells, the apparent molecular weight (MW App ) of wild-type GPVI is roughly 59,500 KDa. Both GPVI N92A and S94A exhibit an increased electrophoretic mobility resulting in an MW App of 52,600. The same increase in electrophoretic mobility is obtained following enzymatic deglycosylation of wild-type GPVI with PNGase F (Figure 2A) but not Endo H (not shown), suggesting that this increase results from the disruption of N-linked glycosylation at the consensus site N 92 -G-S 94 . GPVI was not detectable in lysates of mock transfected COS-7 cells by this ligand blot assay, as evident in Figure 2A .
The relative affinity of SDS-denatured, N-deglycosylated mutants and wild-type GPVI for CVX was also evident in this ligand blot assay. Based on optical scanning and then normalization for transfection efficiency, the binding of N92A was decreased to about 14%, while the binding of S94A was deceased to about 6%.
Effect of tunicamycin on GPVI. COS-7 cells expressing wild-type GPVI were cultured for 48 hours in the presence of 0.5 µg/ml tunicamycin or an equal volume of the carrier DMSO, as a negative control. As shown in a ligand blot (Figure 2B ), tunicamycin treatment resulted in an increase in electrophoretic mobility equivalent to that of the mutant N92A. Moreover, the binding of biotin-CVX was significantly attenuated, as evident in the marked decrease in the intensity of the band.
Adhesion of COS-7 transfectants expressing mutant GPVI. COS-7 Cells
expressing FcRγ and wild-type GPVI adhered well to either CVX or CRP ( Figure 2C ).
The mean adhesion of transfectants expressing either N92A or S94A was decreased to about 60% that of wild-type GPVI ( Figure 2C) . However, the level of expression in COS-7 was not particularly strong, and the variability of this transient expression system precluded a more quantitative evaluation of the impact of these mutations on adhesion. (Figure 3A) , prominent protein bands with the MW App expected of wild-type GPVI (roughly 59.5 KDa) were detected in SDS lysates of 1G4, 1C2 and 1E3, whereas no band was observed in mock transfected cells.
The intensity of the 1G4 band was actually somewhat greater than that of the other samples, but it is clear that cotransfection of FcRγ was not required for efficient synthesis of GPVI. A comparison of surface expression and adhesive properties of the transfected cell lines (Figure 3B ) confirmed the lack of requirement for exogenous FcRγ. Moreover, the specificity of the transfected GPVI for CRP is enforced by the complete absence of adhesion to the control peptides PPG and PPA ( Figure 3B ).
To confirm that 1G4 expresses GPVI that is associated with endogenous Dami
FcRγ, we showed that transfected GPVI was co-precipitated from 1G4 lysates by rabbit polyclonal antibody specific for human FcRγ (Figure 3C) . GPVI was not co-precipitated by the same antibody from lysates of mock transfected cells (not shown).
Comparison of GPVI mutants. Dami cell lines stably transfected with wild-type GPVI and mutants N92A, S94A or L95H were then generated using the same protocol in the absence of exogenous FcRγ. For comparative functional assays, representative clones that exhibited comparable surface expression were selected, as determined by the binding in flow cytometry of murine monoclonal anti-human GPVI antibody 204-11 ( Table 1) .
The level of total GPVI in each clone was also measured by western blot using our murine monoclonal anti-human GPVI antibody LJ6.5. The level of GPVI in lysates of cells producing each of these mutants was indistinguishable from that found in
lysates of cells producing wild-type GPVI (not shown). Thus, quantitative expression of GPVI does not appear to be affected by any of these three substitutions.
A comparison of the adhesion of these cell lines to CVX or CRP ( Figure 3D) confirmed that: 1) for L95H, adhesion to CVX is unaffected and adhesion to CRP is actually increased by 40%; 2) for N92A and S94A, adhesion to CVX is decreased to roughly 75%, while adhesion to CRP is decreased to roughly 20%. Thus, these two substitutions disrupt the ability of GPVI to bind to CRP and, to a lesser extent, CVX.
The fact that the binding of antibody 204-11 to N92A and S94A is equivalent to that of wild-type GPVI, (Table 1) , even though each exhibits reduced ability to adhere to CVX or CRP (Figure A) , is not an inconsistency. Moroi et al. 19 reported that 204-11 binds to a region "near", but not necessarily at, the collagen binding site of GPVI. Our results indicate that neither N92A nor S94A disrupts the epitope(s) recognized by 204-11.
Adhesion to Horm type I collagen was more complex, because Dami cells also express another collagen receptor, the integrin α2β1. However, as reported by Lecut et al. 17 and Lagrue-Lak-Hal et al. 18 , conditions can be established to distinguish the relative contributions of GPVI and α2β1 to adhesion under static conditions, since the latter requires divalent cations and is specifically inhibited by the monoclonal antibody 6F1. The results are depicted in Figure 4 . In the presence of divalent cations (2 mM CaCl 2 and 1 mM MgCl 2 ; Figure 4A ), the adhesion of Dami transfected with wt GPVI or L95H were equivalent, while modest decreases were seen with adhesion of Dami transfected with N92A or S94A (average decreases equal to 11 and 18%, respectively).
In the presence of divalent cations and the monoclonal antibody 6F1 (Figure 4B ), the contribution of the integrin α2β1 is inhibited, and the residual adhesion reflects the For personal use only. on November 12, 2017. by guest www.bloodjournal.org From contribution of GPVI. Again, L95H had no effect, but adhesion mediated by N92A and S94A were decreased, on average, by 65% and 70%, respectively. The results obtained in the presence of 2 mM EDTA ( Figure 4C ) were comparable to those seen in the presence of 6F1. Average inhibition by N92A and S94A were 65% and 70%, respectively. Adhesion of L95H in the presence of EDTA was again comparable to that of wt GPVI. These results confirm that these substitutions in the sequence of GPVI affect GPVI-dependent adhesion to type I collagen without an effect on the concomitant adhesion mediated by integrin α2β1. Moreover, despite the over expression of GPVI in these Dami cell transfectants, endogenous α2β1 still contributes substantially to total adhesion to type 1 collagen in this static system. It has been proposed that the binding sites on GPVI for CVX and CRP are not identical. Using HEL cells expressing recombinant human GPVI, Lecut et al. 10 reported that labeled CVX binds to 65,000 sites with a Kd of 0.35 nM and that cell adhesion to collagen (Horm collagen; equine tendon collagen type I) was inhibited by CVX with an IC 50 of 0.08 nM. On the other hand, CRP had a modest effect on cell adhesion to collagen, which was inhibited by a maximum of only 40% at CRP concentrations of 2.5 µg/ml or higher. Adhesion of the same cells to solid-phase CVX was efficiently inhibited by collagen (IC 50 , 10 µg/ml), but an inhibition of only 20% was attained with CRP at concentrations up to 50 µg/ml. Finally, adhesion to CRP was inhibited fully by either collagen (IC 50 , 2.5 µg/ml) or CVX (IC 50 , 0.06 nM). These results were interpreted to mean that CVX and CRP bind to distinct but overlapping sites on GPVI, but could also be explained by differences in the relative affinity of each ligand for GPVI.
At the same time, the hypothesis of two distinct and overlapping sites received support from the comparative inhibition of three monoclonal anti-GPVI antibodies, 9E18, 3F8, and 9O12, which recognize distinct epitopes and do not cross-compete 10 . 9E18
inhibits binding of human recombinant GPVI to collagen by 45%, and binding to CRP by 85%, but has no effect on binding to CVX. 3F8 inhibits binding to CVX by 55% and to CRP by 50% but has little effect on binding to collagen (10% inhibition). 9O12 inhibits completely the binding of GPVI to CRP, inhibits binding to CVX by up to 80% and binding to collagen by up to 85% 10, 17 . A synergistic inhibition was observed by the combination of 9O12 and 3F8. 
